This unique international conference provides a platform for all pharmaceutical scientists, internists and primary care physicians to discuss and learn about all the important international breakthrough developments in drug discovery and on new therapeutics.

This conference organized by Eureka Science with the support of the Higher Colleges of Technology, UAE, focuses on the interdisciplinary fields of drug discovery, drug therapy and translational medicine.

After the overwhelming success of the previous conferences held in Dubai in February 2008, 2010 and 2011 (where many Nobel Laureates attended), the fourth conference promises to be a much larger event with over 500 talks delivered and 36 thematic sessions with poster presentations and an associated commercial exhibition.

Throughout the course of the four day conference, you will have the opportunity to both network and hear leaders from the international pharmaceutical, academic and clinical communities.

http://www.icddt.com

Although altered glucose metabolism was first noted as a characteristic of tumor cells by Otto Warburg in the 1920s, the molecular underpinning for this observation did not begin to be appreciated fully until the past decade. This area has exploded over the last five years with the identification of extensive interactions of genuine tumor suppressor genes and oncogenes with metabolic control. The increased biosynthetic needs of tumor cells demand a reprogramming of cellular metabolism, which also creates increased energy demands and makes tumor cells more vulnerable to interventions targeting their metabolism. The goal of the Keystone Symposia meeting on Cancer and Metabolism is to bring together leaders in the fields of cancer and metabolic control with those studying the signaling pathways linking and governing each. The latest discoveries will be discussed as well as how this knowledge can be exploited to design future cancer therapeutics. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Advances in Hypoxic Signaling: From Bench to Bedside, which will share a keynote address and a plenary session with this meeting.

http://www.keystonesymposia.org/12Q3

It is our pleasure to invite you to the 13th European Congress: Perspectives in Lung Cancer, 9–10 March 2012, in Amsterdam, The Netherlands. Focusing on state-of-the art information on treatment and diagnosis, this Congress will provide attendees with valuable data for the management of patients with lung cancer.

Guided by an interactive format, Perspectives in Lung Cancer will not only provide a comprehensive overview of the most significant advances in lung cancer treatment, but will also leave attendees with valuable take home information. Lectures, meetthe- expert sessions, and panel discussions, will aid attendees in confirming their current practices, increase their knowledge of lung cancer and optimize their patient care.

Nearly 1,000 physicians, nurses, and other healthcare professionals attend Perspectives in Lung Cancer, annually, making it one of THE must attend lung cancer conferences. Past participants value the scope and depth of the information on disease biology, management, and research presented, and must return each year for the newest updates. As lung cancer research and treatment are ever-evolving, this comprehensive focus on the multimodal management of lung cancer in Europe is sure to be a rewarding educational experience for attendees to share.

We hope you will be able to join us for this valuable, educational two day meeting. Set against the backdrop of Amsterdam, a flourishing, industrious and cosmopolitan European city, which enjoys state-of-the-art technology and architectural developments, this Congress is not to be missed!

http://www.perspectivesinlungcancer.com

Organized by top academic experts in lung cancer and thoracic malignancies, this is THE thoracic CME Conference that you should attend: Lung cancer specialists from a wide range of disciplines will share information on the latest developments in basic, clinical and translational research.

In 2008 the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) joined forces to present the first edition of a biennial meeting addressing the scientific and educational needs of healthcare professionals treating malignant lung diseases. Now, following the success of the first two events, and on behalf of both societies, it gives us great pleasure to introduce the 3rd European Lung Cancer Conference (ELCC), 18–21 April 2012 in Geneva, Switzerland. We believe that a regular meeting on the topic of lung cancer plays a vital role in providing an updated overview of prevention, screening, diagnosis, treatment modalities and results of basic, clinical and translational research. This event should foster and enable fruitful interaction at a multidisciplinary level in order to strengthen an integrated approach to diagnosis and treatment of lung cancer.

We encourage you to save the date of this important European Conference and look forward to welcoming you to Geneva in 2012.

http://www.esmo.org/events/lung-2012-elcc.html